Clinical trials · Michigan
Small Cell Lung Carcinoma clinical trials in Michigan
We’re tracking 83 recruiting small cell lung carcinoma studies with a site in Michigan — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT04928846RecruitingPhase 3
Telisotuzumab vedotin vs docetaxel for advanced non-squamous lung cancer
This trial tests an investigational drug (telisotuzumab vedotin) against the standard chemotherapy docetaxel in people with a certain type of non-squamous lung cancer that has high levels of a protein called c-Met. It may offer a new treatment option for those whose cancer has progressed after initial therapy.
Ypsilanti, MichiganAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Detroit, MichiganAges 12 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Grand Rapids, MichiganAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Grand Rapids, MichiganAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
Detroit, MichiganAges 18 years+ - NCT05467748RecruitingPhase 1/Phase 2
Study drug combo for advanced lung cancer after PD-1 treatment
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Ann Arbor, MichiganAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Detroit, MichiganAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Kalamazoo, MichiganAges 18 years+ - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Dearborn, MichiganAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Grand Rapids, MichiganAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Grand Rapids, MichiganAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Detroit, MichiganAges 18 years+ - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Chelsea, MichiganAges 18 minutes+ - NCT06073431Recruiting
Study on weight loss types in advanced cancer
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
Iron Mountain, MichiganAges 18 years+ - NCT06077760RecruitingPhase 3
Personalized cancer vaccine plus Keytruda for lung cancer after surgery
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
Ann Arbor, MichiganAges 18 years+ - NCT06116682RecruitingPhase 2
Targeted treatment for MET-positive advanced lung cancer
This trial tests a targeted therapy for people with advanced non-small cell lung cancer whose tumors have extra copies of the MET gene. It's for those whose cancer has progressed after at least one prior treatment.
Dearborn, MichiganAges 18 years+ - NCT06225427RecruitingPhase 1
Gilteritinib for advanced ALK-positive lung cancer
This trial tests a drug called gilteritinib for people with a specific genetic type of lung cancer (ALK-positive) that has spread and has been treated before. You may be eligible if you have already tried at least one targeted therapy, and your cancer is still growing.
Ann Arbor, MichiganAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Grand Rapids, MichiganAges 18 years+ - NCT06343402RecruitingPhase 1
Study of BBO-8520 for advanced KRAS G12C lung cancer
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
Detroit, MichiganAges 18 years+ - NCT06400472RecruitingPhase 1
Study of LY4170156 for advanced solid tumors
This study tests a new drug called LY4170156 for people with certain advanced solid tumors. It aims to see if the drug is safe and how well it works.
Grand Rapids, MichiganAges 18 years+ - NCT06418204Recruiting
Cannabis use study for cancer patients in community clinics
This study looks at the benefits and risks of using cannabis or cannabinoids for cancer patients. It aims to help understand how these products affect symptoms and quality of life during chemotherapy or immunotherapy.
Alma, MichiganAges 18 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Farmington Hills, MichiganAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Grand Rapids, MichiganAges 18 years+
Where these studies are running in Michigan
Institutions with a site for the recruiting small cell lung carcinoma studies listed above.
- START Midwest · 8 studies
- Henry Ford Health · 5 studies
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor · 5 studies
- Trinity Health Saint Joseph Mercy Oakland Hospital · 5 studies
- Cancer Hematology Centers - Flint · 4 studies
- Genesee Hematology Oncology PC · 4 studies
- Trinity Health IHA Medical Group Hematology Oncology - Brighton · 4 studies
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital · 4 studies
What taking part in a small cell lung carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Small Cell Lung Carcinoma trials in other states
Common questions
- Are there small cell lung carcinoma clinical trials in Michigan?
- Yes. We're currently tracking 83 recruiting small cell lung carcinoma studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a small cell lung carcinoma study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a small cell lung carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New small cell lung carcinoma studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.